Abstract 192P
Background
Studies of apatinib monotherapy suggest that ARAE (proteinuria, hand-foot syndrome [HFS] and hypertension) may predict clinical outcomes in patients with AGC; however, this phenomenon has not been reported in patients receiving apatinib + chemotherapy. We evaluated the potential association between ARAE and efficacy outcomes of apatinib +chemotherapy for AGC.
Methods
We reviewed two prospective trials of patients treated with apatinib + chemotherapy (POF or paclitaxel alone), a phase II study (ESMO-ASIA 2018) and a phase I study (ESMO 2022). POF was paclitaxel 135 mg/m2 over 3 h followed by leucovorin 400 mg/m2 and oxaliplatin 85 mg/m2 over 2 h; then 5-FU 2,400 mg/m2 continuous infusion over 46 h. Drugs were started days 1 and 15 of each 28-day cycle. Paclitaxel alone was 80 mg/m2 days 1, 8, and 15 of every 28-day cycle. Presence of any ARAE in the first 4 weeks of therapy was assessed and the primary outcome was overall survival (OS). OS was estimated using Kaplan-Meier with the log-rank test. Hazard ratios (HRs) were calculated by univariate and multivariate Cox proportional regression models.
Results
The number of participants was 43 (POF, n=41; paclitaxel alone, n=2). In the first 4 weeks of treatment, 22 (51.2%) had any grade proteinuria, 13 (30.0%) had any grade HFS, and 14 (32.6%) had any grade hypertension. The presence of proteinuria or HFS was associated with prolonged median OS ([months] proteinuria 5.93 vs. 19.10; HR 0.40, 95% CI 0.20-0.79; P=0.0065; HFS 8.92 vs. 22.57 ; HR 0.48, 95% CI 0.23-0.98; P=0.04) and progression-free survival ([PFS] proteinuria 3.50 vs. 9.60 ; HR 0.46, 95% CI 0.23-0.91; P=0.022; HFS 6.40 vs. 10.67 ; HR 0.54, 95% confidence interval (CI) 0.27-1.07; P=0.073 ). 24 (55.8%) patients had one (any grade) proteinuria or HFS in the first 4 weeks, which was associated with prolonged median OS (6.77 vs. 16.35 ; HR 0.47, 95% CI 0.24-0.93; P=0.031) and PFS (4.20 vs. 8.75; HR 0.55, 95% CI 0.28-1.08; P=0.080).
Conclusions
Antiangiogenesis-related proteinuria and HFS may be biomarkers to predict antitumor efficacy of apatinib + chemotherapy in AGC. Future prospective studies are needed to validate findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract